3-chloro-4-hydroxy-5-nitrobenzaldehyde | 98555-61-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-chloro-4-hydroxy-5-nitrobenzaldehyde
• 英文别名: 5-Chlor-3-nitro-4-hydroxybenzaldehyd
• CAS: 98555-61-4
• 化学式: C₇H₄ClNO₄
• 分子量: 201.566
• InChiKey: CGDACEQOAJDMNY-UHFFFAOYSA-N

物化性质

• 熔点：
  158 °C
• 沸点：
  267.6±40.0 °C(Predicted)
• 密度：
  1.634±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-chloro-4-hydroxy-5-nitrobenzaldehyde 在 sodium dithionite 、 hydrazine hydrate 、 potassium hydroxide 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 26.5h， 生成 1-(5-(2-mercapto-7-chlorobenzoxazol-5-yl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone
  参考文献：
  名称：

  Discovery of new antitubercular agents by combining pyrazoline and benzoxazole pharmacophores: design, synthesis and insights into the binding interactions

  摘要：

  The present study is aimed at combining two well-known pharmacophores (pyrazoline and benzoxazole nucleus) to design and synthesize a series of new benzoxazole-based pyrazoline derivatives. In vitro antitubercular evaluation against Mycobacterium tuberculosis H(37)Rv and multidrug-resistant TB (MDR-TB) strains showed that most of the target compounds displayed potent activity (MIC similar to 0.625-25 mu g/mL). Few compounds were found to be better than isoniazid against MDR-TB (MIC = 3.25 mu g/mL). In order to gain insights into the plausible binding motifs, the target compounds were docked into enoyl-acyl carrier protein (ACP) reductase, a molecular target of isoniazid. Many compounds were successfully docked into the active site of enoyl-ACP reductase and all the docked compounds occupied the same hydrophobic binding pocket and interacted mostly by dispersion interactions with the neighboring residues Met103, Met155, Tyr158, Met199, Ile202, Ile215, and Leu218. Contribution of the three pharmacophoric fragments (pyrazoline, benzoxazole and aryl ring) towards protein-ligand binding was evaluated at semi-empirical quantum mechanics level. The interaction energies suggested that most of the binding was governed by the benzoxazole moiety followed by pyrazoline and aryl rings.

  DOI：

  10.1007/s00044-013-0815-x
• 作为产物：
  描述：

  3-氯-4-羟基苯甲醛 在 硝酸 、 溶剂黄146 作用下， 反应 6.0h， 以58.4%的产率得到3-chloro-4-hydroxy-5-nitrobenzaldehyde
  参考文献：
  名称：

  [EN] NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS
  [FR] NOUVEAUX COMPOSÉS DIHYDROPYRIMIDINE-2(1H)-ONES EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHION RÉDUCTASE

  摘要：

  本发明涉及一种新型二氢嘧啶-2(1H)-酮化合物，可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括这些化合物的药物组合物，以及制备和使用这些化合物的方法。

  公开号：

  WO2011038204A1

文献信息

• SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20210386721A1

  公开（公告）日：2021-12-16

  Disclosed are a substituted phenylpropenylpyridine derivative, a preparation method therefor and the use thereof as a PD-1/PD-L1 inhibitor. In particular, disclosed are a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method therefor and the use thereof. The definition of each group in the formula is detailed in the description and claims.

  揭示了一种取代苯丙烯基吡啶衍生物，其制备方法以及其作为PD-1/PD-L1抑制剂的用途。具体地，揭示了一种符合式(I)的化合物或其药用可接受的盐、立体异构体、溶剂合物或前药，以及其制备方法和用途。公式中每个基团的定义在描述和权利要求中详细说明。
• Benzoxazin-3-ones and derivatives thereof as therapeutic agents
  申请人：——

  公开号：US20040121996A1

  公开（公告）日：2004-06-24

  The present invention provides compounds of Formula I 1 wherein W, Q, E, D, R 6 , R 7 , R 8 , Y, K, R 9 , R 10 , R 12 , G, and the double bond denoted “*” have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

  本发明提供了I式化合物，其中W，Q，E，D，R6，R7，R8，Y，K，R9，R10，R12，G和表示为“*”的双键具有规范中定义的任何值，并且其药学上可接受的盐，可用作治疗疾病和病症的药物，包括炎症性疾病，心血管疾病和癌症。还提供了包含一种或多种I式化合物的制药组合物。
• POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
  申请人：Brown Jason W.

  公开号：US20120094992A1

  公开（公告）日：2012-04-19

  Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.

  以下式子的化合物被提供用于抑制Poly (ADP-ribose) Polymerase (PARP)的作用： 其中变量在此定义。还提供了制备该化合物的药物组合物、工具箱和制造品、中间体的方法以及使用该化合物的方法。
• Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors
  申请人：Sun Xicheng

  公开号：US20120208817A1

  公开（公告）日：2012-08-16

  The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型二氢嘧啶-2(1H)-酮化合物，其可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括这种化合物的制药组合物，以及制造和使用它们的方法。
• Poly (ADP-ribose) polymerase (PARP) inhibitors
  申请人：Brown Jason W.

  公开号：US08669249B2

  公开（公告）日：2014-03-11

  Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.

  以下公式的化合物被提供用于抑制Poly (ADP-ribose) Polymerase (PARP)的使用：其中变量在此定义。还提供了包含这些化合物的药物组合物、工具包和制造物品，以及制造这些化合物有用的方法和中间体，以及使用这些化合物的方法。